It is possible that the robust anti-AML activity of narazaciclib (AUC < 2.4) for EOL-1, KASUMI-1, MONO-MAC-1, OCI-AML-5, OCI-AML-2, and SKM-1 cells might be attributed to the inhibition of CSF1R. This evidence concerns the gene CSF1R and acute myeloid leukemia.